Restrictions put in place to help reduce the spread of COVID-19 are beginning to be eased in the U.S. and many other countries. At the same time, however, there is ever-present fear that this will trigger a second wave of infections. In an environment characterized by such uncertainty, the author of today’s article notes, “market watchers are looking to the insiders, hoping insights from their activity can steer them towards returns” – and she highlights “five compelling stocks snapped up by corporate insiders recently.” For more, CLICK HERE.
The Right Stocks Right Now: 3 Penny Stocks With “Strong Buy” Ratings And “Massive Upside Potential”
“We’re not in a true bull market – not by a long shot – but the recent bear has pushed prices down and the current rally is opening up the prospects of gains. All that remains is finding the right stocks to buy,” advises the author of today’s article. He proceeds to highlight three penny stocks that might fit the bill. For these three penny stocks with Strong Buy analyst ratings and significant upside potential based on analyst price targets, CLICK HERE.
The Upsides Of Low-Priced Stocks – And 2 Top Biotech Stocks Under $10
When it comes to low-priced (under-$10) stocks, the author of today’s article acknowledges that “These types of equities…tend to be exceptionally risky and highly volatile from a price standpoint.” But he also points out some significant upsides to buying low-priced stocks, including the fact that they can, on occasion, “deliver substantial returns on capital within an exceedingly short period.” With this in mind, he proceeds to highlight what may be two of the top stocks under $10 right now: a pair of biotech stocks that seemingly remain undervalued despite heating up in recent weeks. For more, CLICK HERE.
The Bears vs. The Bulls On “The Hottest Battleground Stock In Cancer Treatment”
It’s “arguably the most intense battleground stock the biotech oncology sector has ever witnessed,” declares the author of today’s article in regards to the stock he proceeds to examine – one which has a passionate group betting on it on one side and an equally passionate group betting against it (and calling it “One of the biggest scams of the 21st century”) on the other. So, with critical phase 3 clinical trial results for its only prominent drug candidate set to be released in May, what’s causing so much controversy for this stock, and who’s right – the bears or the bulls? CLICK HERE.
2 “Compelling” Biotech Stocks That Just Won The Ultimate Prize (FDA Approval)
FDA approval is the ultimate prize in the biotech industry – and one of the few major catalysts for biotech stocks. As a result, having just received FDA approval for key products, the two biotech stocks highlighted in today’s article have made their way onto Wall Street’s radar – and may be compelling biotech picks. For these two biotech stocks, CLICK HERE.
3 Biotech/Pharma Stocks With Potential Clinical Trial Catalysts This Quarter
“In light of the ongoing COVID-19 pandemic, a number of pharma companies have postponed new study starts and have paused enrollment/screening in their clinical trials. However, companies that have completed an analysis of their trial data are sticking to the timeline of reporting the results,” notes the author of today’s article, who proceeds to take a look at three biotech/pharma companies that are still expected to report clinical trial results this quarter. For these three companies – and their potential catalysts due this quarter – CLICK HERE.
3 Underappreciated Cannabis Stocks With High Upside Potential
How are marijuana stocks performing in the current environment? Today’s article notes that, “Despite solid indications that cannabis operations are one of the few sectors not impacted by the global economic shutdown, all of the stocks are far off the yearly highs” – and this creates an opportunity among underappreciated cannabis stocks. Such as? The author highlights three picks – including one with implied upside potential of nearly 500% in the next 12 months. For more, CLICK HERE.
Large- And Small-Cap Biotech Picks For Aggressive Growth Accounts
While the five biotech stocks highlighted in today’s article are a mix of large-cap leaders in the space and small-cap companies with massive upside potential, they are all best suited for aggressive growth accounts with a higher risk tolerance. For these five biotech stocks that have been identified by RBC as top picks – including one firm with a potential coronavirus treatment and other firms that RBC believes have “gigantic upside” beyond coronavirus – CLICK HERE.
3 High-Growth Small-Cap Stocks For Your Stimulus Check
If you’re fortunate enough to not need your stimulus check to cover bills or basic needs, what stocks might you want to consider buying with those funds instead? The author of today’s article advises that “now might be the time to get aggressive and seek out higher-growth small-cap stocks for your portfolio” – and highlights three in particular to consider buying with your stimulus check. For these three stocks, CLICK HERE.
Trading Patterns Fit For A Pandemic
“Right now, the coronavirus is creating the hottest sector we’ve seen in years. It’s bigger than the bitcoin craze and pot stocks,” declares the author of today’s article, who has been making money during the coronavirus market crash by trading strategically and sticking to his favorite trading patterns – which he shares, along with some specific examples where he has taken advantage of those patterns recently. For more, CLICK HERE.